- Home
- LDWY vs CERO Comparison
LDWY vs CERO Comparison
Compare LDWY & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- CERO
- Stock Information
- Founded
- LDWY 1990
- CERO 2017
- Country
- LDWY United States
- CERO United States
- Employees
- LDWY N/A
- CERO N/A
- Industry
- LDWY Advertising
- CERO
- Sector
- LDWY Consumer Discretionary
- CERO
- Exchange
- LDWY Nasdaq
- CERO Nasdaq
- Market Cap
- LDWY 9.2M
- CERO 3.5M
- IPO Year
- LDWY 1991
- CERO N/A
- Fundamental
- Price
- LDWY $4.73
- CERO $9.79
- Analyst Decision
- LDWY
- CERO Strong Buy
- Analyst Count
- LDWY 0
- CERO 2
- Target Price
- LDWY N/A
- CERO $45.00
- AVG Volume (30 Days)
- LDWY 6.5K
- CERO 3.3M
- Earning Date
- LDWY 08-18-2025
- CERO 08-13-2025
- Dividend Yield
- LDWY N/A
- CERO N/A
- EPS Growth
- LDWY N/A
- CERO N/A
- EPS
- LDWY N/A
- CERO N/A
- Revenue
- LDWY $42,183,000.00
- CERO N/A
- Revenue This Year
- LDWY N/A
- CERO N/A
- Revenue Next Year
- LDWY N/A
- CERO N/A
- P/E Ratio
- LDWY N/A
- CERO N/A
- Revenue Growth
- LDWY 425.12
- CERO N/A
- 52 Week Low
- LDWY $3.02
- CERO $6.71
- 52 Week High
- LDWY $5.53
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- LDWY 50.82
- CERO 50.09
- Support Level
- LDWY $4.85
- CERO $8.12
- Resistance Level
- LDWY $5.12
- CERO $13.14
- Average True Range (ATR)
- LDWY 0.16
- CERO 2.83
- MACD
- LDWY -0.05
- CERO 0.39
- Stochastic Oscillator
- LDWY 7.84
- CERO 19.58
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.